Schizophrenia Clinical Trials in Chicago
View 37 new treatments for Schizophrenia in Chicago, IL, and nearby areas, such as Naperville. Every day, Power helps hundreds of schiz patients connect with leading medical research.Filter Results
Condition
All
How old are you?
Trial Phase
All
Trial Status
All
Cariprazine for Pediatric Schizophrenia
AbbVie Clinic, Hoffman Estates + 3 more
This trial is testing the safety and effectiveness of cariprazine in children and teens with schizophrenia, bipolar I disorder, or autism. The goal is to see if the medication is safe and beneficial for use in these young patients.Show More
Verified
Recruiting
No Placebo Trial
Phase 3
Est. 5 - 8 Weeks
ABBVIE INC.
Study Director
Emraclidine for Schizophrenia
Cerevel Clinic, Hoffman Estates + 3 more
This trial aims to evaluate the safety and tolerability of a medication called emraclidine, taken by mouth, in adults with schizophrenia.
Verified
Recruiting
No Placebo Trial
Phase 2
Est. 5 - 8 Weeks
Erica Koenig, PhD
Study Director
Clozapine vs Risperidone for Psychosis
Research Clinic, Chicago + 1 more
The CLOZAPINE study is designed as a multisite study across 5 sites and is a clinical trial, involving human participants who are prospectively assigned to an intervention. The study will utilize a stringent randomized, double-blinded, parallel group clinical trial design. B2 group will serve as psychosis control with risperidone as medication control. The study is designed to evaluate effect of clozapine on the B1 participants, and the effect that will be evaluated is a biomedical outcome. The study sample will be comprised of individuals with psychosis, including 1) schizophrenia, 2) schizoaffective disorder and 3) psychotic bipolar I disorder. The investigators plan to initially screen and recruit n=524 (from both the existing B-SNIP library and newly-identified psychosis cases, \~50% each) in order to enroll n=320 (B1 and B2) into the RCT.Show More
Recruiting
Phase 4
Est. 3 - 12 Weeks
Carol Tamminga, M.D.
Principal Investigator
KarXT for Schizophrenia
Karuna Clinic, Chicago + 3 more
This trial tests KarXT, a combination of two drugs, for people who haven't improved with their current treatment. KarXT aims to balance brain functions and reduce side effects. The study will look at improvements in health and daily life. KarXT has shown positive results in earlier tests.Show More
Recruiting
Phase 3
Est. 5 - 8 Weeks
Ronald Marcus, MD
Study Director
Long-term Safety of Iclepertin for Schizophrenia
Boehringer Ingelheim Clinic, Chicago + 1 more
This study is open to adults with schizophrenia who took part in a previous CONNEX study (study 1346-0011, 1346-0012, or 1346-0013). The purpose of this study is to find out how well people with schizophrenia can tolerate a medicine called Iclepertin in the long term. Participants take Iclepertin as tablets once a day for 1 year. In addition, all participants take their normal medication for schizophrenia. Participants are in the study for a little more than 1 year. During this time, they visit the study site about 13 times and get about 9 phone calls from the study team. The doctors collect information on any health problems of the participants. Doctors also regularly check the participants' symptoms of schizophrenia.Show More
Recruiting
No Placebo Trial
Phase 3
Est. 6 - 12 Weeks
Unregistered Study Lead
Research Team
Brilaroxazine for Schizophrenia
Reviva Clinic, Chicago + 1 more
This trial tests Brilaroxazine, a daily pill, in patients with severe mental health issues. It aims to improve mood and reduce symptoms. The study lasts for more than a year.Show More
Recruiting
Phase 3
Est. 4 - 6 Weeks
Medical Director
Study Director
SEP-363856 for Schizophrenia
Sunovion Clinic, Chicago + 1 more
This trial is testing a new schizophrenia medication called SEP-363856 in people who have already started using it. The goal is to see if it is safe and effective over several months. The medication works by affecting brain chemicals to help reduce symptoms of schizophrenia.Show More
Waitlist
No Placebo Trial
Phase 3
Est. 3 - 12 Weeks
CNS Medical Director
Study Chair
KarXT for Schizophrenia
Karuna Clinic, Chicago + 5 more
This trial tests the safety and tolerability of KarXT, a combination of two drugs, in schizophrenia patients who haven't responded well to their current treatments. KarXT aims to improve symptoms and manage side effects better than existing medications. KarXT (xanomeline plus trospium) is an emerging treatment for schizophrenia, showing promise in managing total, positive, and negative symptoms.Show More
Recruiting
No Placebo Trial
Phase 3
Est. 4 - 6 Weeks
Bristol-Myers Squibb
Study Director
Valbenazine for Schizophrenia
Neurocrine Clinic, Chicago + 1 more
This trial is testing whether adding the medication valbenazine can help people with schizophrenia who haven't improved enough with regular antipsychotic drugs. Valbenazine aims to balance brain chemicals to reduce symptoms.Show More
Recruiting
Phase 3
Est. 3 - 12 Weeks
Clinical Development Lead
Study Director
Dexmedetomidine for Agitation in Schizophrenia and Bipolar Disorder
BioXcel Clinic, Elgin + 3 more
In this study, an investigational medication named BXCL501 is being tested for the treatment of episodes of agitation associated with bipolar I and bipolar II disorder, schizophrenia, schizoaffective and schizophreniform disorder. This study compares the study drug to a placebo.Show More
Waitlist
Phase 3
Est. 5 - 8 Weeks
Robert Risinger, MD
Study Chair
Page 1 of 2
Frequently Asked Questions
Explore related conditions